Posted Nov. 5, 2013 at 9:01 a.m.

Premium Lock BioCryst on track to file flu treatment for FDA approval by year's end

Published: 2013-11-05 09:01:33
Updated: 2013-11-05 09:01:33

BioCryst BioCryst

Drug developer BioCryst Pharmaceuticals (NASDAQ:BCRX), whose influenza treatment peramivir is moving toward a drug filing with the Food and Drug Administration, narrowed its net loss for the third quarter to $8.0 million, or 14 cents per share, from $9.7 million a year ago....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2017 WRAL TechWire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders